MX2020009813A - Composiciones y metodos para tratar el prurito. - Google Patents

Composiciones y metodos para tratar el prurito.

Info

Publication number
MX2020009813A
MX2020009813A MX2020009813A MX2020009813A MX2020009813A MX 2020009813 A MX2020009813 A MX 2020009813A MX 2020009813 A MX2020009813 A MX 2020009813A MX 2020009813 A MX2020009813 A MX 2020009813A MX 2020009813 A MX2020009813 A MX 2020009813A
Authority
MX
Mexico
Prior art keywords
compositions
methods
treating pruritus
pruritus
treating
Prior art date
Application number
MX2020009813A
Other languages
English (en)
Inventor
Wendy Huang Chern
Chan- Jung Li
Shu- Wen Kuo
David Chih- Kuang Chou
Yu- En Tien
Original Assignee
Lumosa Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lumosa Therapeutics Co Ltd filed Critical Lumosa Therapeutics Co Ltd
Publication of MX2020009813A publication Critical patent/MX2020009813A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente se describen composiciones farmacéuticas tópicas de éster de sebacoilo dinalbufina (SDE) y métodos para usar tales composiciones para tratar prurito, dolor y afecciones inflamatorias.
MX2020009813A 2018-03-29 2019-03-28 Composiciones y metodos para tratar el prurito. MX2020009813A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862650108P 2018-03-29 2018-03-29
PCT/US2019/024706 WO2019191511A1 (en) 2018-03-29 2019-03-28 Compositions and methods for treating pruritus

Publications (1)

Publication Number Publication Date
MX2020009813A true MX2020009813A (es) 2020-11-11

Family

ID=68054657

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009813A MX2020009813A (es) 2018-03-29 2019-03-28 Composiciones y metodos para tratar el prurito.

Country Status (13)

Country Link
US (2) US20190298702A1 (es)
EP (1) EP3755328A4 (es)
JP (1) JP2021525225A (es)
KR (1) KR20200138730A (es)
CN (1) CN112040948A (es)
AU (1) AU2019243571A1 (es)
BR (1) BR112020019094A2 (es)
CA (1) CA3094710A1 (es)
IL (1) IL277463A (es)
MX (1) MX2020009813A (es)
RU (1) RU2020130919A (es)
TW (1) TWI729371B (es)
WO (1) WO2019191511A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113797167B (zh) * 2020-06-16 2024-05-10 苏州恩华生物医药科技有限公司 一种塞纳布啡的储库制剂
WO2022175973A1 (en) * 2021-02-18 2022-08-25 Navin Saxena Research And Technology Private Limited An injectable composition for long term delivery of nalbuphine or nalbuphine ester prodrug or its salts and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130759C (es) * 1965-10-07
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US6225321B1 (en) * 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
US6503944B1 (en) * 1999-05-26 2003-01-07 The Andrew Jergens Company Anhydrous skin care composition
US6967023B1 (en) * 2000-01-10 2005-11-22 Foamix, Ltd. Pharmaceutical and cosmetic carrier or composition for topical application
EP1149836B1 (en) * 2000-04-27 2003-02-26 Oliver Yoa-Pu Hu Polynalbuphine derivatives
US20080069779A1 (en) * 2003-08-04 2008-03-20 Foamix Ltd. Foamable vehicle and vitamin and flavonoid pharmaceutical compositions thereof
US20070093517A1 (en) * 2005-10-24 2007-04-26 Gary Newton Local anesthetic compositions
EP3266444A1 (en) * 2010-02-26 2018-01-10 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
CA2857189A1 (en) * 2011-12-08 2013-06-13 Rigel Pharmaceuticals, Inc. Topical formulation for administering a compound
US20140112957A1 (en) * 2012-10-19 2014-04-24 Oliver Yao-Pu Hu Analegisic (Sebacoyl dinalbuphine ester) PLGA controlled release formulation form
RU2017101102A (ru) * 2014-06-13 2018-07-16 Треви Терапьютикс, Инк. Способы лечения зуда
CA2987378C (en) * 2015-05-28 2023-08-01 Lumosa Therapeutics Co., Ltd. Pharmaceutical formulations for sustained release of sebacoyl dinalbuphine ester

Also Published As

Publication number Publication date
IL277463A (en) 2020-11-30
EP3755328A4 (en) 2021-11-10
WO2019191511A1 (en) 2019-10-03
EP3755328A1 (en) 2020-12-30
CN112040948A (zh) 2020-12-04
KR20200138730A (ko) 2020-12-10
TWI729371B (zh) 2021-06-01
US20190298702A1 (en) 2019-10-03
JP2021525225A (ja) 2021-09-24
RU2020130919A3 (es) 2022-04-29
RU2020130919A (ru) 2022-04-29
AU2019243571A1 (en) 2020-10-15
TW202002977A (zh) 2020-01-16
CA3094710A1 (en) 2019-10-03
BR112020019094A2 (pt) 2020-12-29
US20220362226A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
WO2019222112A8 (en) Mcl-1 inhibitors
MX2018012486A (es) Composiciones para aplicacion topica de compuestos.
MX2018006578A (es) Formulaciones farmaceuticas topicas para tratar afecciones inflamatorias.
EA033395B1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
MX2023008031A (es) Inhibidores de la cinasa 2 de control general no desrepresible (gcn2) y usos de los mismos.
MX2018009773A (es) Heteroarilos inhibidores de peptidilarginina desiminasa 4 (pad4).
MX2015011374A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2023002507A (es) Inhibidores de cd73.
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
CR20190537A (es) Inhibidores pirazólicos de magl
EA201792496A1 (ru) Способы лечения воспаления или нейропатической боли
PH12020551728A1 (en) Stat3 inhibitors
MX2022003166A (es) Moduladores de il-17a y usos de los mismos.
MX2018006700A (es) Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4).
MX2019004030A (es) Inhibidores del receptor de glucocorticoides.
GEP20217318B (en) Pyrazole magl inhibitors
MX2017015923A (es) Inhibidores de indolamina-2,3-dioxigenasa (ido).
NZ788133A (en) Cd73 inhibitors
WO2017177024A8 (en) METHODS OF TREATING OCULAR DISORDERS
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
MX2020009813A (es) Composiciones y metodos para tratar el prurito.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
EP3737384A4 (en) METHODS AND COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CONDITIONS ASSOCIATED WITH ALPHA-SYNUCLEIN